FibroBiologicsFBLG
Market Cap: $112M
About: FibroBiologics Inc is a clinical-stage cell therapy company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including degenerative disc disease, multiple sclerosis, wound healing, and certain cancers, and potential extension of life applications including thymic and splenic involution reversal.
Employees: 8
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
550% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 6
325% more capital invested
Capital invested by funds: $5.18M [Q1] → $22M (+$16.9M) [Q2]
194% more funds holding
Funds holding: 17 [Q1] → 50 (+33) [Q2]
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
12.03% more ownership
Funds ownership: 1.47% [Q1] → 13.5% (+12.03%) [Q2]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
EF Hutton Jason Kolbert 14% 1-year accuracy 2 / 14 met price target | 403%upside $16 | Buy Maintained | 13 Sept 2024 |
EF Hutton Jason Kolbert 14% 1-year accuracy 2 / 14 met price target | 403%upside $16 | Buy Initiated | 4 Sept 2024 |
Financial journalist opinion
Based on 3 articles about FBLG published over the past 30 days